Hackensack Meridian School of Medicine Professor and Director of Cardiac Research at Hackensack University Medical Center named American Heart Association Investigator of the Year

Taya Glotzer, MD, FACC, FHRS, honored at the New Jersey Heart Ball on June 10

Taya Glotzer, MD, FACC, FHRS, has been named the 2022 American Heart Association (AHA) Researcher of the Year. The award is given to a researcher who conducts cutting-edge research in the area of ​​heart disease and/or stroke.

“Research is the lifeblood of the American Heart Association and recognizing individuals who are making progress is very important to us,” said Peter Cary, executive director for the New Jersey region with the AHA. “Dr. Glotzer and his work deserve recognition, and we are so grateful for his dedication to helping people live longer, healthier lives.

Dr. Glotzer, who is a professor of medicine at the Hackensack Meridian School of Medicine and director of cardiac research at Hackensack University Medical Center, received the award at the American Heart Association’s annual gala, the New Jersey Heart Ball, on June 10.

“Dr. Glotzer is one of our extremely talented physician-scientists,” said Robert C. Garrett, CEO of Hackensack Meridian Health. “We applaud his achievement.”

“We are so proud of Dr. Glotzer’s contributions to great science and innovation driven by our network,” said Ihor Sawczuk, MD, FACS, president of academics, research and innovation for Hackensack Meridian. Health. “Our research-engaged clinician promotion program continues to pay dividends for our patients – and national organizations are taking notice.”

Widely published and regularly invited by organizations such as the American College of Cardiology, American Heart Association, Heart Rhythm Society and European Society of Cardiology to present nationally and internationally, Dr. Glotzer has been interested in long to stroke prevention and to studying the relationship between atrial fibrillation (AF) and stroke.

She published one of the first articles identifying the association of AF detected by an implanted heart device with poor clinical outcomes; stroke and death, in 2003. Dr. Glotzer was the principal investigator of a landmark trial (TRENDS), which showed that a device detecting AF for more than 5.5 hours in the last 30 days doubled the risk of stroke. She was on the writing group for the Heart Rhythm Society expert consensus statement on remote monitoring and the European Heart Rhythm Association consensus document on device-detected subclinical AF.

In response to the pandemic, Hackensack University Medical Center launched a COVID-specific cardiology research group, of which Dr. Glotzer is a member. The group is collaborating to shed light on the effect of COVID on the heart and blood vessels. In this capacity, Dr. Glotzer found abnormalities on admission electrocardiograms that predicted poor outcomes in patients hospitalized with COVID-19. She presented her findings at the Heart Rhythm Society’s 2021 Annual Scientific Sessions.

Dr. Glotzer received his medical degree from New York University School of Medicine in 1987 and completed his residency, cardiology fellowship, and electrophysiology fellowship at NYU Langone Medical Center. She is certified in clinical cardiac electrophysiology. She has been the Director of Cardiac Research at Hackensack University Medical Center since 2005, in addition to a full-time cardiac electrophysiology practice at Hackensack University Medical Center. She is a Fellow of the American College of Cardiology and a Fellow of the Heart Rhythm Society. “I love seeing and treating my patients, some of whom I’ve known for 20 years,” Dr. Glotzer said. “I feel privileged to be able to take care of them.”

For more information on Hackensack Meridian Health cardiovascular services, visit www.hackensackmeridianhealth.org/en/Services/Heart-Care. For more information on Hackensack Meridian School of Medicine, visit www.hmsom.org/.


Hackensack Meridian School of Medicine, New Jersey’s first private medical school in more than 50 years, welcomed its first class of students in 2018 to its On3 campus in Nutley and Clifton. Meridian Hackensack Health took up independent operation in July 2020. The school’s vision is that every person in New Jersey and the United States, regardless of race or socioeconomic status, will enjoy the highest levels of well-being. reared in an economically and behaviorally sustainable manner. The school’s unique curriculum emphasizes the connection between basic science and clinical relevance, through an integrated curriculum in a collaborative, team-oriented environment. The school prides itself on its outreach activities, through programs such as Human Dimension, which is active in New Jersey communities.


Leave a Comment